Microsoft has taken a lead from its co-founder Bill Gates' philanthropic efforts. The computing giant is making its Azure cloud platform available to Ebola researchers who need help with the storage and analysis of data.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug prices surge ever higher, spurring a growing backlash from payers.
In this constantly shifting panorama you'll find a group of executives who are forging new paths for others to follow. This year, the third for Fierce, we present the men and women whose influence is being felt across the industry.
Influence, of course, isn't always a force for good. But it can be. To be truly influential in an industry, you need to be able to persuasively explain new methods that can exert a powerful hold on colleagues in the same global field. Some of this year's group have excelled in that regard.
We hope you enjoy this year's report. And please offer any suggestions you may have for next year's project on the influentials.
POPULAR COMMENT THREADS
The National Institutes of Health (NIH) has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding. Read more >>
Boehringer Ingelheim has completed a pilot project to assess whether it is best served by its current electronic laboratory notebook technology. The process led to Boehringer deciding to phase out use of multiple in-house systems and replace them with IDBS' E‑WorkBook Suite.
Dr. Patrick Soon-Shiong has teamed up with the University of Oxford and others to further the United Kingdom's plan to build the "NASA of biomedicine." Some of the £141 million ($227 million) investment is earmarked for establishing computing infrastructure to support the U.K.'s genomics project.
Geisinger Health System has added another component to the genomic variant database it is helping to create as part of a $25 million National Institutes of Health initiative. The new addition gives patients the option to submit their genetic test results and other health information to a registry.
The National Science Foundation has awarded Cornell University a grant to cut the time it takes to transfer data.
While there is a well-established path from seed funding to exit for web startups, genomics plays with big ambitions require investors with deep pockets and an appetite for risk. Bryan Johnson seemingly has both and has set up a $100 million fund with the objective of turning "crazy" ideas into "viable" businesses.
From Our Sister Sites
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.